Search results
6 days ago · The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
5 days ago · Moderna said Friday that approval of its RSV vaccine was based on clinical trial data showing that even about four months after someone gets the shot, the vaccine had an 83.7% efficacy at ...
5 days ago · Moderna filed for FDA approval on data from a late-stage trial that showed its vaccine was 83.7% effective at preventing at least two symptoms of RSV, such as cough and fever. The company's shares ...
6 days ago · Moderna, the biotech that rose to fame for making one of the world’s first Covid-19 vaccines, has hit a new milestone: its first non-Covid product, which could give the company a much-needed ...
5 days ago · Moderna’s shot, called mRESVIA, was cleared for use in adults 60 and older and will compete with products that arrived last year from GSK Plc and Pfizer Inc. Those two generated about $2.4 ...
5 days ago · Moderna’s shot is the third RSV vaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to ...
5 days ago · Moderna's vaccine was approved for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older, but with a label indicating the shot was 79% effective at preventing ...
